BioNTech (NASDAQ:BNTX) Shares Down 1.9%

BioNTech SE (NASDAQ:BNTX) fell 1.9% on Thursday . The company traded as low as $112.72 and last traded at $113.47. 408,266 shares were traded during mid-day trading, a decline of 47% from the average session volume of 777,595 shares. The stock had previously closed at $115.62.

Analyst Ratings Changes

Several research analysts have recently weighed in on BNTX shares. HC Wainwright restated a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research note on Monday, September 16th. UBS Group upped their target price on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday. Bank of America increased their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, HSBC raised BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $124.54.

BioNTech Trading Down 0.2 %

The firm has a market capitalization of $26.69 billion, a P/E ratio of 224.56 and a beta of 0.23. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $90.81 and a 200 day simple moving average of $90.63.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the prior year, the firm posted ($0.86) earnings per share. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. As a group, research analysts forecast that BioNTech SE will post -2.8 EPS for the current year.

Institutional Trading of BioNTech

Large investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC bought a new stake in BioNTech in the second quarter worth $223,000. Granite Bay Wealth Management LLC bought a new stake in shares of BioNTech in the 2nd quarter worth about $1,483,000. Scientech Research LLC bought a new position in shares of BioNTech in the 2nd quarter valued at about $1,127,000. Deerfield Management Company L.P. Series C grew its position in BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after acquiring an additional 24,426 shares in the last quarter. Finally, Employees Retirement System of Texas increased its stake in BioNTech by 15.7% during the second quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock worth $2,442,000 after acquiring an additional 4,115 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.